Direct medical cost of erythropoiesis-stimulating agents in anaemia treatment of chronic renal failure patient: a literature review

Néphrologie & thérapeutique
Florence RanchonLaure Huot

Abstract

Management of anaemia in chronic renal insufficiency (CRI) represents an important medico-economic challenge because of the great number of patients and the cost of the erythropoiesis-stimulating agent (ESA). The aim of this study was to identify determinants of the costs associated with these treatments in order to choose, with equal efficacy, the most efficient ASE. A bibliographic research was realised by Medline database interrogation. Among the direct medical costs, five studies showed that acquisition of epoetine alfa (EA) compared to darbepoetin alfa (DA) was less expensive. Concerning the costs associated with the route of administration, the subcutaneous injection (SC) of epoetine allowed a gain in costs because of the decrease of doses compared to the intravenous (IV) route. The switch from EA in SC to DA in IV, for hemodialysis patients, was associated with a reduction of the number of injections and with a treatment's cost lower by DA than by EA. Costs related to the regimen of administration, notably those related to nursing, medical and pharmaceutical time, were negligible towards those associated to the acquisition of the ASE. Finally, the costs of the therapeutic follow-up and treatment of the adverse effects of...Continue Reading

References

Apr 1, 1995·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·D A RevickiR L Benz
Jan 19, 1999·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·J S Kaufman
Oct 8, 1999·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Jul 28, 2001·Kidney International·F LocatelliUNKNOWN European/Australian NESP 980202 Study Group
Mar 15, 2002·The American Journal of Medicine·Denise M HynesJohn R Feussner
Aug 30, 2002·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Anatole BesarabJohn Hornberger
Nov 13, 2002·Kidney International·Yves VanrenterghemUNKNOWN European/Australian NESP 970200 Study Group
May 2, 2003·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Mario FraticelliFerruccio Conte
Dec 13, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Erwin HeckingFriedrich K Port
Dec 13, 2003·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Francesco LocatelliPhilip J Held
Mar 18, 2004·Current Medical Research and Opinion·Anthony MorrealeMonica Schaefer
Jun 23, 2004·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Francesco LocatelliUNKNOWN European Best Practice Guidelines Working Group
Jun 24, 2004·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Ronald L PisoniFriedrich K Port
Jul 22, 2004·Current Medical Research and Opinion·Gilbert Deray
Apr 13, 2005·Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association·Walter H HörlBjörn Wikström
May 17, 2005·Transfusion clinique et biologique : journal de la Société française de transfusion sanguine·H Ansart-PirenneF Noizat-Pirenne
Jul 29, 2005·Clinical Nephrology·K Shalansky, J Jastrzebski
Aug 23, 2005·American Journal of Kidney Diseases : the Official Journal of the National Kidney Foundation·Françoise Macron-NoguèsHubert Allemand
Sep 29, 2005·The Annals of Pharmacotherapy·Donald F BrophyLori A Proeschel
Dec 8, 2005·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Eric J Kruep, Lorne E Basskin
May 20, 2006·Current Medical Research and Opinion·Frank J PapatheofanisCatherine Tak Piech
Sep 13, 2006·Néphrologie & thérapeutique·Faissal TarrassHenri Colomb
Jun 29, 2007·Nephron. Clinical Practice·David N ChurchillRon Goeree
Sep 8, 2007·American Journal of Health-system Pharmacy : AJHP : Official Journal of the American Society of Health-System Pharmacists·Francis VekemanMei Sheng Duh
Nov 8, 2007·JAMA : the Journal of the American Medical Association·Josef CoreshAndrew S Levey
Nov 22, 2007·The Annals of Pharmacotherapy·Harminder SikandAyesha Naeem
Dec 2, 2008·Néphrologie & thérapeutique·Michèle KesslerSébastien Koné

❮ Previous
Next ❯

Citations

Feb 8, 2014·Liver International : Official Journal of the International Association for the Study of the Liver·Sabine AmetStanislas Pol

❮ Previous
Next ❯

Related Concepts

Related Feeds

Anemia

Anemia develops when your blood lacks enough healthy red blood cells. Anemia of inflammation (AI, also called anemia of chronic disease) is a common, typically normocytic, normochromic anemia that is caused by an underlying inflammatory disease. Here is the latest research on anemia.

Related Papers

Expert Opinion on Pharmacotherapy
Joel Michels Topf
Nephrology, Dialysis, Transplantation : Official Publication of the European Dialysis and Transplant Association - European Renal Association
Jérôme RossertWilliam McClellan
Nefrología : publicación oficial de la Sociedad Española Nefrologia
José M Mora-GutiérrezNuria García-Fernández
Expert Opinion on Biological Therapy
Isabelle Wauters, Johan Vansteenkiste
© 2021 Meta ULC. All rights reserved